Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Positive results for Roche from longer-term follow-up data for polatuzumab

Positive results for Roche from longer-term follow-up data for polatuzumab

3rd December 2018

Roche has announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, in combination with MabThera®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival of 12.4 months versus the BR arm of 4.7 months in people with relapsed or refractory diffuse large B-cell lymphoma not eligible for a haematopoietic stem cell transplant. Treatment with polatuzumab vedotin plus BR resulted in a 66% reduction in risk of disease progression or death with 40% achieving a complete response compared to 18% in the BR arm. The drug, an anti-CD79b antibody drug conjugate, is currently being investigated for the treatment of several types of non-Hodgkin lymphoma and, in combination with BR, has been granted Breakthrough Therapy Designation and orphan drug designation by the FDA, and PRIority MEdicines designation and orphan drug designation by the EMA, for the treatment of adult patients with R/R DLBCL who are not candidates for haematopoietic stem cell transplantation.
Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development, said: “There is a significant need for new and more effective treatment options for the approximately 40% of people with diffuse large B-cell lymphoma whose disease either does not respond to initial treatment or returns – a situation that is associated with a very poor prognosis that worsens after each relapse. We are delighted that polatuzumab vedotin has demonstrated sustained clinical benefits and has the potential to hopefully improve survival rates in this population. We are working with health authorities to make this novel regimen available to patients worldwide.”

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.